PD-L1 x CD28 TRACIr (JANX009)
Our PDL1-TRACIr drug candidate is designed to bind to immunosuppressive PD-L1 on tumor cells as well as to the CD28 costimulatory receptor on T cells. The CD28 costimulatory domain is masked to prevent off tumor activation of T cells.
Janux is developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific drug candidate (JANX009) that targets both the programmed death-ligand 1 (PD-L1) receptor as well as the co-stimulatory CD28 receptor on T cells.
Our single-masked PD-L1 x CD28 costimulatory bispecific is designed to be unmasked only in the tumor microenvironment and to conditionally agonize CD28 only in the presence of PD-L1, which is often overexpressed by tumors to avoid T cell mediated killing.
Our bispecific molecule is designed to bind to immunosuppressive PD-L1 on tumor cells as well as to the CD28 costimulatory receptor on T cells.
